not a bad research report just went through it. Again the outcome from the CAC mentioned being end of H2 2022
Have to admit the way they summaries the differences between the direct/indirect methods shows flaws in INF's IR team.
But again seems like management are putting their best foot forward. H1 2023 might be a very good time for holders
below was very interesting and highlights the potential rerate we are all waiting for.
not a bad research report just went through it. Again the...
-
- There are more pages in this discussion • 1,010 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
